Cargando…
Systems biology analysis of mitogen activated protein kinase inhibitor resistance in malignant melanoma
BACKGROUND: Kinase inhibition in the mitogen activated protein kinase (MAPK) pathway is a standard therapy for cancer patients with activating BRAF mutations. However, the anti-tumorigenic effect and clinical benefit are only transient, and tumors are prone to treatment resistance and relapse. To el...
Autores principales: | Zecena, Helma, Tveit, Daniel, Wang, Zi, Farhat, Ahmed, Panchal, Parvita, Liu, Jing, Singh, Simar J., Sanghera, Amandeep, Bainiwal, Ajay, Teo, Shuan Y., Meyskens, Frank L., Liu-Smith, Feng, Filipp, Fabian V. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5883534/ https://www.ncbi.nlm.nih.gov/pubmed/29615030 http://dx.doi.org/10.1186/s12918-018-0554-1 |
Ejemplares similares
-
The RAS/mitogen activated protein (MAP) kinase pathway in melanoma biology and therapeutics
por: Jarell, Abel D, et al.
Publicado: (2007) -
Harnessing autophagy to overcome mitogen‐activated protein kinase kinase inhibitor‐induced resistance in metastatic melanoma
por: Verykiou, S., et al.
Publicado: (2018) -
Correlation of P38 Mitogen-Activated Protein Kinase Expression to Clinical Stage in Nasopharyngeal Carcinoma
por: Farhat, Farhat, et al.
Publicado: (2018) -
Metabolic profiling of triple-negative breast cancer cells reveals metabolic vulnerabilities
por: Lanning, Nathan J., et al.
Publicado: (2017) -
A Possible Link of Genetic Variations in ER/IGF1R Pathway and Risk of Melanoma
por: Yuan, Tze-An, et al.
Publicado: (2020)